MDI Therapeutics announces closing of Series A investment
Novi, Michigan – March 21, 2022 – MDI Therapeutics, Inc. (“MDI”), a pharmaceutical company developing novel serpin-based therapies for the treatment of fibrosis and fibroproliferative disorders, is pleased to announce it has closed a Series A financing with Juvenescence Ltd. Juvenescence, a biopharmaceutical company focused on treating aging and age-related disease, will provide MDI with up to $9 million in funding and collaborate with MDI to advance its lead program through Phase 1 clinical trials.
Read More